In this video, Fool bureau chief Brenton Flynn offers three reasons why you might take a pass on Abbott Labs. The company reduced its dividend after spinning off AbbVie, which reduces its appeal to income investors. The loss of AbbVie means Abbott will have to work harder at improving its earnings since its branded pharmaceutical business isn't there to roll out a blockbuster drug.

Follow along in the video below as Brenton details these bearish arguments.